$EBS

2 stories mentioning EBSUpdated 42d ago

Every FINWIRES story that references EBS, newest first.

Emergent BioSolutions Signs $50 Million Contract to Support SAB Biotherapeutics' Lead Program

Emergent BioSolutions (EBS) said Wednesday it has signed a $50 million multi-year agreement with SAB Biotherapeutics (SABS) to help advance SAB-142 lead program in clinical development for autoimmune type 1 diabetes.Under the agreement, $36 million is contingent on future regulatory approval and downstream milestones, according to a statement.Emergent BioSolutions will provide end-to-end development and manufacturing services that are compliant with current good manufacturing practices, the company said.Price: $8.17, Change: $-0.07, Percent Change: -0.79%

$EBS$SABS

Wire55d ago

Emergent BioSolutions Signs $34.5 Million Manufacturing Deal With Substipharm Biologics

Emergent BioSolutions (EBS) said Tuesday it has signed a $34.5 million deal with Substipharm Biologics to support drug substance manufacturing for the Japanese encephalitis vaccine at its Canton, Massachusetts, facility.As part of the agreement, Emergent said it will be the exclusive distributor of the vaccine to the US government, following potential US Food and Drug Administration regulatory clearances.Under a master manufacturing services agreement, Emergent said it will conduct operational and regulatory inspection readiness activities for the vaccine.Emergent shares were up 1.6% in Tuesday trading.Price: $8.16, Change: $+0.13, Percent Change: +1.62%

$EBS

Track with the FINWIRES app suite

FolioX

Track EBS in your portfolio

WheelAI

Analyze EBS options with the wheel strategy

StockInsider

See market sentiment on EBS